Premium
PANCREATICODUODENECTOMY FOR LOCALLY ADVANCED STOMACH CANCER: PRELIMINARY RESULTS
Author(s) -
Chan WengHoong,
Cheow PengChung,
Chung Alexander Y. F.,
Ong HockSoo,
Koong HengNung,
Wong WaiKeong
Publication year - 2008
Publication title -
anz journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.426
H-Index - 70
eISSN - 1445-2197
pISSN - 1445-1433
DOI - 10.1111/j.1445-2197.2008.04646.x
Subject(s) - medicine , exploratory laparotomy , pancreaticoduodenectomy , duodenum , surgery , stomach , chemotherapy , gastrectomy , cancer , neoadjuvant therapy , survival rate , laparotomy , general surgery , pancreas , gastroenterology , breast cancer
Background: Pancreaticoduodenectomy (PD) for locally advanced stomach cancer involving duodenum or/and pancreatic head was controversial and rarely carried out. It was mainly reported from the Japanese institutions. Methods: A review of prospective database from January 2003 to December 2006 of patients who had locally advanced stomach cancer involving duodenum or/and head of pancreas that precluded curative subtotal gastrectomy who underwent diagnostic laparoscopy or exploratory laparotomy to exclude peritoneal metastatic disease. Patients were advised to undergo neoadjuvant chemotherapy before PD. Results: Seven patients underwent PD during the above‐mentioned period. Only four patients had neoadjuvant chemotherapy before PD. The median operative time was 8 h (range 6–9 h). Five patients had combined tranverse colectomy done. There was no 30‐day operative mortality or re‐operation. Three patients developed controlled pancreatic leaks and fistulas that were successfully treated with conservative measures. The length of hospital stay was 10–53 days (median 15 days). Median survival was 13 months and 2‐year survival rate was 60%. Patients who received neoadjuvant chemotherapy seemed to have better survival rate ( P = 0.039). Conclusion: Our initial experience has shown that with careful and stringent patients selection, PD for locally advanced stomach cancer can be carried out with acceptable morbidity and mortality. Early results for patients who received neoadjuvant chemotherapy showed trend towards prolonged survival. However, longer follow up and further patient recruitment are needed to confirm our initial optimistic findings.